scholarly journals P1.03-007 A Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer

2017 ◽  
Vol 12 (11) ◽  
pp. S1953
Author(s):  
Y. Jin ◽  
X. Hu ◽  
M. Chen ◽  
Y. Chen ◽  
X. Shi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Clinicopathological Characteristics ◽  
Survival Outcome ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

Lung Cancer ◽  
2019 ◽  
Vol 136 ◽  
pp. 109-114 ◽  
Author(s):  
Renaud Descourt ◽  
Maurice Perol ◽  
Gaëlle Rousseau-Bussac ◽  
David Planchard ◽  
Bertrand Mennecier ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Inhibitors ◽  
Alk Positive

scholarly journals Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program

2020 ◽  
Vol 16 (15) ◽  
pp. 1031-1041 ◽  
Author(s):  
Huamao M Lin ◽  
Xiaoyun Pan ◽  
Peijie Hou ◽  
Susan Allen ◽  
Pia Baumann ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Next Generation ◽  
Small Cell Lung ◽  
Early Access ◽  
Alk Positive ◽  
Access Program

Aim: To assess time-to-treatment discontinuation (TTD) of brigatinib following treatment with ALK tyrosine kinase inhibitor(s) (TKIs) in patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) receiving brigatinib through the international early access program. Patients & analysis: Analysis was performed for patients with ALK+ NSCLC treated with prior ALK TKIs, including next-generation ALK TKIs. Results: Data for 604 patients (21 countries), including patients with prior next-generation ALK TKIs, were reported. The median TTD of brigatinib in patients with prior crizotinib, alectinib, ceritinib or lorlatinib was 10.0, 8.7, 10.3 and 7.5 months, respectively. Conclusion: Brigatinib appears to be effective and tolerable in real-world clinical practice regardless of prior treatment with first or NG ALK TKIs.

Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP)

2020 ◽  
Author(s):  
David Heredia ◽  
Feliciano Barrón ◽  
Andrés F. Cardona ◽  
Saul Campos ◽  
Jerónimo Rodriguez-Cid ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
World Data ◽  
Alk Positive ◽  
Nsclc Patients

Background: Brigatinib has demonstrated its efficacy as first-line therapy and in further lines for ALK-positive non-small cell lung cancer (NSCLC) patients; however, real-world data in Latin America are scarce. Methods: From January 2018 to March 2020, 46 patients with advanced ALK-positive NSCLC received brigatinib as second or further line of therapy in Mexico and Colombia. The primary endpoint was progression-free survival (PFS); secondary endpoint was time to treatment discontinuation (TTD). Results: At a median follow-up of 9.3 months, the median PFS was 15.2 months (95% CI: 11.6–18.8), and TTD was 18.46 months (95% CI: 9.54–27.38). The estimated overall survival at 12 months was 80%. Safety profile was consistent with previously published data. Conclusion: Brigatinib is an effective treatment for previously treated ALK-positive NSCLC patients in a real-world setting.

Sign in / Sign up

Export Citation Format

Share Document